Tamper evident closure container

Information

  • Patent Grant
  • 11857754
  • Patent Number
    11,857,754
  • Date Filed
    Tuesday, January 3, 2023
    a year ago
  • Date Issued
    Tuesday, January 2, 2024
    10 months ago
Abstract
A closure container that can house a preset drug applicator in an easily accessible manner with tamper evidencing means. The closure container contains a plurality of dosing ribs and a retainer to retain the syringe in a preset dosage amount and preferably has a window to view the barrel of the syringe.
Description
BACKGROUND OF THE INVENTION

Success rates with respect to action taken in response to an emergency situation almost always improve with proper preparation, access to the proper equipment, and speed. This could not be more true than in the case of providing a dose of fluid (e.g., epinephrine to a patient experiencing a severe or life-threatening allergic reaction (anaphylaxis)). According to the National Institute of Allergy and Infectious Diseases, early treatment with epinephrine is beneficial to patients having an anaphylactic episode because the patient could experience a rapid decline in health or death within 30 to 60 minutes. Such early treatment may also be beneficial in patients experiencing seizure activity.


In addition to quick administration of treatment, accurate dosing is crucial because not enough medicine may be ineffective and too much may cause health risks, such as dangerously high blood pressure, stroke, or death. During an anaphylactic event, for example, a health provider may need a larger or smaller dose depending on the size or age of the patient and fumbling with a vial and a needle may add precious seconds before treatment and potential dosing errors.


Further, sterilization is important whenever it comes to administering a drug to a patient through a needle and a health care provider has to know if the needle being used and the drug being administered have not been tampered with. Accordingly, the art of emergency treatment could benefit from a device that promotes quick access to a drug applicator which may be stored in pre-set doses and provides evidence of tampering.


SUMMARY OF THE INVENTION

The present invention relates to a closure container, and more particularly to a container that can house a preset drug applicator in an easily accessible manner with tamper evidencing means.


An embodiment of a method according to the present invention includes filling a syringe with a predetermined amount of fluid and placing the syringe in a container comprising a first casing member, a second casing member coupled to the first casing member at a hinge location, and a fastener capable of securing the first casing member to the second casing member opposite the hinge location, the fastener having a tamper evident pull tab and wherein the first casing member includes at least one catch and the second casing member includes at least one hole configured to be mateable with a catch. The method also includes the steps of closing the container and stacking the container on top of another identical container.


According to another embodiment of a method according to the present invention, the placing step involves configuring the at least one catch to have an L-shape profile, wherein a body of the catch extends perpendicularly from the first casing member and an arm of the catch extends from the body.


According to still another embodiment of a method according to the present invention, the stacking step involves inserting the arm and body of a catch of the container into a hole of another container and sliding the containers in opposite directions relative to one another.


According to yet another embodiment of a method according to the present invention, the predetermined amount of fluid corresponds to one dose of medicine.


According to a further embodiment of a method according to the present invention, the syringe includes a plunger and the dose of medicine corresponds to a predetermined plunger position.


According to a further embodiment of a method according to the present invention, the container further includes a plurality of dosage ribs, a bridge, and a retainer projecting therefrom that are configured to cradle the syringe, and the spacing between dosage ribs relates to the predetermined amount of fluid provided within the syringe.


According to a further embodiment of a method according to the present invention, the container further comprises a window that is transparent to visible light.


According to a further embodiment of a method according to the present invention, the closing step involves viewing the filled syringe within the container through the window.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of a first embodiment of a tamper evident closure container according to the present invention.



FIG. 2 is a perspective view of the container shown in FIG. 1 in an open state and holding a syringe.



FIG. 3 is another perspective view of the container shown in FIG. 1 in an open, empty state.



FIG. 4 is a top plan view of the container shown in FIG. 1.



FIG. 5 is a bottom plan view of the container shown in FIG. 1.



FIG. 6 is a front elevation view of the container shown in FIG. 1.



FIG. 7 is a rear elevation view of the container shown in FIG. 1.



FIG. 8 is a right side elevation view of the container shown in FIG. 1.



FIG. 9 is a left side elevation view of the container shown in FIG. 1.



FIG. 10 is a top plan view of the container as shown in FIG. 3.



FIG. 11 is a bottom plan view of the container as depicted in FIG. 3.



FIG. 12 is a front elevation view of the container as shown in FIG. 3.



FIG. 13 is a rear elevation view of the container as depicted in FIG. 3.



FIG. 14 is a right side elevation view of the container as shown in FIG. 3.



FIG. 15 is a left side elevation view of the container as depicted in FIG. 3.



FIGS. 16-19 depict a progressive method of enclosing a syringe in the first embodiment of the container according to the present invention.



FIG. 20 is a cross-sectional view along line 20-20 of FIG. 19.



FIG. 21 is a perspective view of a plurality of containers according to the first embodiment of the present invention stacked one on top of the other.



FIG. 22 is a selected cut-away view of FIG. 21.



FIG. 23 is a perspective view of a second embodiment of a tamper evident closure container according to the present invention.



FIG. 24 is a perspective view of a plurality of containers according to the second embodiment of the present invention stacked one on top of the other.



FIG. 25 is a cut-away view of selected section FIG. 25 of FIG. 24.





DESCRIPTION OF THE PREFERRED EMBODIMENT

Although the disclosure hereof is detailed and exact to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention which may be embodied in other specific structures. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.


Turning first to FIG. 1, a first embodiment 10 of a closure container according to the present invention is shown. The closure container 10 preferably comprises a single injection-molded piece having a first casing member 100 hingedly attached to a second casing member 200 by at least one hinge 12 (see FIG. 2), which may be a living hinge.


The first casing member 100 may generally be formed along a longitudinal length between and including a first end 102 opposite a second end 104, an outer surface 106, a peripheral edge portion 116 (FIG. 2), a fastener 118, and an inner surface 132 (FIG. 2).


The outer surface 106 of the first casing member 100 extends from the first end 102 to the second end 104 and to the peripheral edge portion 116. The outer surface 106 has a planar portion 108 with a window 110 preferably provided therein and a plurality of catches 112 projecting therefrom.


Each catch 112 preferably has an L-shape profile and extends outward from the planar portion 108, whereby an arm 114 of the L-shape is spaced from and substantially parallel with the planar portion 108 of the outer surface 106, and all of the catches 112 are oriented preferably in the same direction.


The fastener 118 is flexibly connected at or near the peripheral edge portion 116 of the first casing member 100 opposite the hinge 12. The fastener 118 has a width 120, a thickness 122, an exterior surface 124, an interior surface 126, and a tamper-evident pull-tab 130. A barb 128 projects from the interior surface 126 distal to the outer surface 106 of the first casing member 100.


The tamper-evident pull-tab 130 preferably extends substantially perpendicular from the fastener 118 between the barb 128 and the outer surface 106 of the first casing member 100. The tamper-evident pull-tab 130 is preferably offset from the exterior surface 124 of the fastener 118 in a direction away from the container 10 when the fastener 118 is in an engaged position, as discussed further below.


The inner surface 132 of the first casing member 100 can be seen in FIGS. 2 and 3. The inner surface 132 extends from the first end 102 to the second end 104 and to the peripheral edge portion 116, and preferably has an at least substantially planar portion 134. As shown here, a bridge 136 with a notch 138 projects from the planar portion 134 of the inner surface 132 near the first end 102 to or near the peripheral edge portion 116.


A retainer 140 extends from the planar surface 134 to or near the peripheral edge portion 116 and comprises a first wall 142, with a first wall notch 144, and a second wall 146, with a second wall notch 148, substantially parallel to the first wall 142.


A plurality of dosing ribs 152 project from the planar portion 134 to or near the peripheral edge portion 116 and are spaced between the second end 104 and the second wall 146 of the retainer 140. Each dosing rib 152 has a notch 154, an innermost side 156 (hidden), and an outermost side 158. The spacing between the dosing ribs 152 relates to the predetermined dosage provided in a syringe 50 (FIG. 2) to be contained within the closure container 10. The preferable dosing amounts for which the ribs 152 will be spaced are 0.25 mL, 0.5 mL, 0.75 mL, and 1.0 mL, but other dosing amounts are contemplated.


The second casing member 200 may be seen in FIGS. 2 and 3 as well. The second casing member 200 has a first end 202 opposite a second end 204, an outer surface 206, a peripheral edge portion 216, and an inner surface 232.


The outer surface 206 of the second casing member 200 extends from the first end 202 to the second end 204 and to the peripheral edge portion 216. The outer surface 206 preferably has an at least substantially planar portion 208 with a plurality of holes 260 (FIG. 5) therein which are sized, positioned, and configured to be mateable with the catches 112 of the first casing member 100 of another closure container 10.


As shown in FIGS. 10 and 11, the outer surface 206 of the second casing member 200 has a recess 262 with a width 264 slightly greater than the width 120 of the fastener 118 and a depth 266 preferably similar to the thickness 122 of the fastener 118. A slot 268 sized and configured to receive the barb 128 of the fastener 118 is provided within the recess 268.


Looking back to FIGS. 2 and 3, the inside surface 232 of the second casing member 200 is shown. The inside surface 232 of the second casing member 200 is preferably substantially similar to the inside surface 132 of the first casing member 100. As shown here, the inner surface 232 extends from the first end 202 to the second end 204 and to the peripheral edge portion 216, and preferably has a planar portion 234. As shown here, a bridge 236 with a notch 238 projects from the planar portion 234 of the inner surface 232 near the first end 202 to or near the peripheral edge portion 216.


A retainer 240 extends from the planar portion 208 to or near the peripheral edge portion 216 and comprises a first wall 242, with a first wall notch 244, and a second wall 246, with a second wall notch 248, substantially parallel to the first wall 242. The first wall 242 is spaced apart from the second wall 246 a distance 250.


A plurality of dosing ribs 252 project from the planar portion 234 of the inner surface 232 to or near the peripheral edge portion 216 and are spaced between the second end 204 and the second wall 246 of the retainer 240. Each dosing rib 252 has a notch 254, an innermost side 256, and an outermost side 258. The spacing between the dosing ribs 252 relates to the predetermined dosage provided in a syringe 50 (FIG. 2) to be contained within the closure container 10. The preferable dosing amounts for which the ribs 252 will be spaced are 0.25 mL, 0.5 mL, 0.75 mL, and 1.0 mL, however, other dosing amounts are contemplated.


Additionally or alternatively, the dosing ribs 152 of the first casing member 100 may be staggered from the dosing ribs 252 of the second casing member 200 to provide more dosing options while still providing secure support of the syringe 50 and the plunger 52.


Additionally or alternatively, the first casing member 100 or the second casing member 200 may not contain the respective dosing ribs, retainer, or the bridge; instead being configured simply to cover the other casing member 200,100.


Looking back to FIG. 1 and also to FIGS. 4-9, the closure container 10 is depicted in from various views with the syringe 50 positioned within the container 10 and the fastener 118 engaged with the second casing member 200. As shown, when the container 10 is in a closed position, the fastener 118 preferably resides substantially within the recess 262, with the barb 128 received within the slot 268.


The material from which the closure container 10 is formed is preferably initially transparent. The window 110 is preferably formed by covering the area in which the window 110 will be located, treating at least the outer surfaces 106,206 of the first casing member 100 and the second casing member 200, respectively, to decrease the transparency of those surfaces, and removing the covering to reveal the window 110. The treatment may be performed by any process now known or later discovered, including but not limited to, chemical etching, mechanical etching (e.g., sand blasting), or during the molding process using textured dies.


Continuing to look at FIG. 1, a syringe 50 can be viewed through the window 110 in a pre-set dosage configuration, ready for use. The window 110 is preferably located at least radially outward from the barrel 64 of the syringe 50 to provide a care provider with a view of the syringe 50 and preferably the dosage amount provided in the barrel 64 without having to open the closure container 10.


Directing attention to FIGS. 16-19, the installation of the syringe 50 into the container 10 is shown. FIG. 16 illustrates the syringe 50 with a predetermined dosage provided in the barrel 64 prior to placement within the second casing member 200; however, the syringe 50 may be placed within the first casing member 100 as well, as shown in FIG. 17.


Looking to FIG. 17, with reference to FIG. 16, the flange 60 of the syringe 50 is placed within the retainer 140 of the first casing member 100 with a portion of the barrel 64 received by the notch 144 of the first wall 142 and another portion of the barrel 64 received by the notch 138 of the bridge 136. Preferably, the distance 150 between the first and second walls 142,146 of the retainer 140 (FIG. 10) is preferably slightly greater than the thickness 62 of the syringe flange 60.


The top 54 of the plunger 52 has a topside surface 56 and an underside surface 58. When installed within the container 10, the underside surface 58 of the syringe top 54 preferably resides against or near the outermost side 158 of the respective dosing rib 152. The placement of the flange 60 within the retainer 140 and the top 54 against the dosing rib 152 reduces the likelihood that the syringe 50 will be accidentally discharged prior to use.



FIG. 18 illustrates the closing of the container 10 with the first and second casing members 100,200 rotating about the hinge 12 (FIG. 17) and adjoining the first casing member peripheral edge portion 116 (FIG. 17) with the second casing member peripheral edge portion 216 (FIG. 17). The barrel 64 of the syringe 50 is thereby also received within the bridge notch 238, the retainer 240, and the respective dosing rib notch 254 of the second casing member 200 (see FIG. 17).


Looking to FIGS. 19 and 20, the engagement of the fastener 118 is shown. The fastener 118 is wrapped around the outside surface 206 of the second casing member 200 within the recess 262. The barb 128 is engageably received within the slot 268 to retain the fastener 118 in the engaged position.


When the time comes for the syringe 50 to be removed from the container 10, the health care personnel will pull the tamper-evident pull-tab 130 away from the container 10 which will tear through the fastener 118 and sever the fastener's connection between the first and second casing members 100,200, thus allowing the container 10 to be opened and the syringe 50 to be removed.


Removal of the tamper-evident pull-tab 130 permanently detaches at least a portion of the fastener 118 from the first casing member 100 when pulled to gain access to the syringe 50. Therefore, tampering with the fastener 118 or the tamper-evident pull-tab in an attempt to gain access to the syringe 50 will be visibly noticeable by a tear in the fastener 118.



FIGS. 21 and 22 demonstrate how multiple containers 10A,10B,10C may be stacked one on top of the other.


As shown in greater detail in FIG. 22, a mateable stacking interaction between a catch 112A and a hole 260B is shown. The interaction allows the containers 10A,10B to be removably interlocked. The catch 112A, along with the other three catches (not shown), of the first container 10A are inserted within the holes 260B of the second container 10B and the containers 10A,10B, are slid in opposite directions relative to one another to place the arm 114A of the first container 10A adjacent to the inner surface 232B of the second container second casing member 200B. These actions are depicted by the dashed lines in FIG. 21.



FIG. 23 illustrates a second embodiment 20 of the closure container according to the present invention. The closure container 20 has tabs 470 projecting from the planar portion 408 of the second casing member outer surface 406 and apertures 390 (FIG. 24) provided through the planar portion 308 of the first casing member outer surface 306. The apertures 390 are alignable and mateable with the tabs 470 of a corresponding closure container 20.


Each tab 470 has a width 472 (FIG. 24), an inward face 476, and an outward face 480. The tabs 470 preferably extend substantially perpendicular away from the outside surface planar portion 408 and comprise a protuberance 478, or similarly shaped protrusion, on the inward face 476 at or near the distal end portion 482 (FIG. 25) of each tab 470. Alternatively, it is contemplated that the protuberance 478 may protrude from the outward face 480.


The apertures 390 have a width 392 and an abutting surface 396. The width 392 of the apertures 390 is preferably slightly greater than the width 472 of the tabs 470.



FIGS. 24 and 25 demonstrate how multiple containers 20A,20B,20C may be stacked by inserting the tabs 470B of a second container 20B within the apertures 390A of a first container 20B. This action is depicted by the dashed lines in FIG. 24. In this fashion, stacking of these embodiments 20 require only a singular directional movement, rather than the compound movement that may be utilized to stack cases according to the first embodiment 10.



FIG. 25 more closely illustrates the interaction between a tab 470B of the second container 20B is received within an aperture 390 of the first container 20A to provide a releasable connection between the two containers 20A,20B. Preferably, the inner face 476B of the tab 470B is substantially flush with the abutting surface 396A of the aperture 390A, whereby the protuberance 478B of the tab 470B is in contact with the planar portion 334A of the first casing member inner surface 332A and the first container's second casing member outer surface planar portion 308A is flush with the second container's first casing member outer surface planar portion 408B.


The foregoing is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.

Claims
  • 1. A method comprising the steps of: filling a syringe with a predetermined amount of fluid;placing the syringe in a container comprising a first casing member, a second casing member coupled to the first casing member at a hinge location, and a fastener capable of securing the first casing member to the second casing member opposite the hinge location, the fastener having a tamper evident pull tab and wherein the first casing member includes at least one catch and the second casing member includes at least one hole configured to be mateable with a catch;closing the container; andstacking the container on top of another identical container.
  • 2. The method of claim 1, the placing step further comprising: configuring the at least one catch to have an L-shape profile, wherein a body of the catch extends perpendicularly from the first casing member and an arm of the catch extends from the body.
  • 3. The method of claim 2, the stacking step further comprising: inserting the arm and body of a catch of the container into a hole of another container; andsliding the containers in opposite directions relative to one another.
  • 4. The method according to claim 3, wherein the predetermined amount of fluid corresponds to one dose of medicine.
  • 5. The method according to claim 4, wherein the syringe includes a plunger and the dose of medicine corresponds to a predetermined plunger position.
  • 6. The method according to claim 5, wherein the container further comprises a plurality of dosage ribs, a bridge, and a retainer projecting therefrom that are configured to cradle the syringe, and wherein the spacing between dosage ribs relates to the predetermined amount of fluid provided within the syringe.
  • 7. The method according to claim 6, wherein the container further comprises a window that is transparent to visible light.
  • 8. The method according to claim 7, wherein the closing step further comprises: viewing the filled syringe within the container through the window.
RELATED APPLICATIONS

This application is a continuation of the co-pending U.S. patent application Ser. No. 17/840,267 filed Jun. 14, 2022 and entitled “Tamper Evident Closure Container,” which is a divisional application of issued U.S. patent application Ser. No. 16/506,753 filed Jul. 9, 2019 and entitled “Tamper Evident Closure Container,” now U.S. Pat. No. 11,357,908, which is a continuation application of issued U.S. patent application Ser. No. 15/059,428 filed Mar. 3, 2016 and entitled “Tamper Evident Closure Container,” now U.S. Pat. No. 10,342,914, which is a continuation application of issued U.S. patent application Ser. No. 14/599,202 filed Jan. 16, 2015 and entitled “Tamper Evident Closure Container”, now U.S. Pat. No. 9,333,289, all of which are incorporated herein by reference in their entireties.

US Referenced Citations (279)
Number Name Date Kind
2687157 Cowan Aug 1954 A
2884123 Dann Apr 1959 A
2939603 Young Jun 1960 A
2955705 Krueger et al. Oct 1960 A
3235069 Bennett Feb 1966 A
3287075 Batke et al. Nov 1966 A
3407961 Box Oct 1968 A
3902621 Hidding Sep 1975 A
4087018 Tebbutt May 1978 A
4432462 Newkirk Feb 1984 A
4453666 Gordon Jun 1984 A
4671408 Raines Jun 1987 A
4979616 Clanton Dec 1990 A
5031768 Fischer Jul 1991 A
5039002 Spamer Aug 1991 A
5090564 Chimienti Feb 1992 A
5154291 Sur Oct 1992 A
5207367 Dunn et al. May 1993 A
5353929 Foster Oct 1994 A
5356006 Alpern et al. Oct 1994 A
5358624 Roshdy et al. Oct 1994 A
5368576 Brown et al. Nov 1994 A
5372254 Gross Dec 1994 A
5375717 Roshdy Dec 1994 A
5379900 Gregg et al. Jan 1995 A
5384103 Miller Jan 1995 A
5392918 Harrison Feb 1995 A
5395003 Matsuda Mar 1995 A
5402886 Mcglinch Apr 1995 A
5407070 Bascos et al. Apr 1995 A
5415287 Hamano et al. May 1995 A
5417926 Bouveret May 1995 A
5435448 Kempen Jul 1995 A
5441152 Estes Aug 1995 A
5447230 Gerondale Sep 1995 A
5447231 Kastenhofer Sep 1995 A
5469964 Bailey Nov 1995 A
5497601 Gonzalez Mar 1996 A
5501341 Van Es Mar 1996 A
5506015 Frederiksen Apr 1996 A
5511679 Beck Apr 1996 A
5526928 Yabe et al. Jun 1996 A
5556388 Johlin, Jr. Sep 1996 A
5564565 Yamada Oct 1996 A
5566828 Claes Oct 1996 A
5582599 Daneshvar Dec 1996 A
5607055 Bettinger Mar 1997 A
5611428 Banerian Mar 1997 A
5615772 Naganuma Apr 1997 A
5678719 Adams et al. Oct 1997 A
5690222 Peters Nov 1997 A
5692635 Farrell et al. Dec 1997 A
5709310 Kretz Jan 1998 A
5718334 Demel Feb 1998 A
5738213 Whiting et al. Apr 1998 A
5758775 Lowe Jun 1998 A
5758793 Forsyth et al. Jun 1998 A
5765682 Bley et al. Jun 1998 A
5769222 Banerian Jun 1998 A
5775498 Kashanchi Jul 1998 A
5792422 Lin et al. Aug 1998 A
5797510 Carrier et al. Aug 1998 A
5799790 Ziegert et al. Sep 1998 A
5816429 Kobayashi Oct 1998 A
5817065 Dufresne et al. Oct 1998 A
5842567 Rowe et al. Dec 1998 A
5848691 Morris et al. Dec 1998 A
5848895 Martin et al. Dec 1998 A
5865335 Farrell et al. Feb 1999 A
5887743 Stahlecker et al. Mar 1999 A
5895374 Slashed Apr 1999 A
5931332 Mygatt et al. Aug 1999 A
5934498 Jordan Aug 1999 A
5947284 Foster Sep 1999 A
5947296 Castora Sep 1999 A
5950827 Odom et al. Sep 1999 A
5960956 Langanki et al. Oct 1999 A
6003714 Buermann Dec 1999 A
6009998 Webinger Jan 2000 A
6017322 Snoke et al. Jan 2000 A
6036043 Erfgen et al. Mar 2000 A
6036671 Frey Mar 2000 A
6047825 Samuels Apr 2000 A
6053313 Farrell et al. Apr 2000 A
6053905 Daignault, Jr. et al. Apr 2000 A
6059107 Slashed et al. May 2000 A
6065597 Pettersson et al. May 2000 A
6068121 Mcglinch May 2000 A
6074367 Hubbell Jun 2000 A
6089397 Van Melle Jul 2000 A
6142334 Kristensson Nov 2000 A
6155420 Phillips Dec 2000 A
6186325 Schmidt et al. Feb 2001 B1
6228324 Hasegawa et al. May 2001 B1
RE37252 Hollister Jul 2001 E
6258078 Thilly Jul 2001 B1
6279743 Ballard et al. Aug 2001 B1
6341709 Wilson Jan 2002 B1
6350232 Hascoet et al. Feb 2002 B1
6354487 Muise, Jr. Mar 2002 B1
6357589 Schmidt et al. Mar 2002 B2
6375006 Samuels Apr 2002 B1
6401956 Heinicke et al. Jun 2002 B1
6409717 Israelsson et al. Jun 2002 B1
6415921 Ye et al. Jul 2002 B2
6478780 Shields Nov 2002 B1
6511461 Jonsson Jan 2003 B2
6547072 Whiting et al. Apr 2003 B2
6568434 Zinger May 2003 B2
6569852 Sodemann May 2003 B1
6576918 Fu et al. Jun 2003 B1
6578709 Kavanagh et al. Jun 2003 B1
6585942 Bussell et al. Jul 2003 B1
6588588 Samuels Jul 2003 B2
6588619 Cardarelli Jul 2003 B2
6595362 Penney et al. Jul 2003 B2
6604647 Luburic Aug 2003 B1
6634498 Kayerod et al. Oct 2003 B2
6669046 Sawada et al. Dec 2003 B1
6712214 Wintermute et al. Mar 2004 B1
6719135 Armijo Apr 2004 B2
6732858 Chang Ou May 2004 B1
6736805 Israelsson et al. May 2004 B2
6779675 Cousseau Aug 2004 B2
6797973 Zens Sep 2004 B2
6814717 Lin Nov 2004 B2
6822253 Martin et al. Nov 2004 B1
6848574 Israelsson et al. Feb 2005 B1
6851568 Herrmann Feb 2005 B2
6854616 Steffan Feb 2005 B2
6871740 Cao Mar 2005 B1
6884393 Hui et al. Apr 2005 B2
6890310 Fracavilla et al. May 2005 B2
6892881 Leitch May 2005 B2
6902057 Duffy Jun 2005 B2
6964656 Saint-ramon et al. Nov 2005 B2
6991096 Gottlieb et al. Jan 2006 B2
6994823 Hight, III Feb 2006 B2
7021484 Herrmann Apr 2006 B2
7028837 Yanke et al. Apr 2006 B2
7066912 Nestenborg et al. Jun 2006 B2
7104399 Duffy et al. Sep 2006 B2
7147122 Heinicke Dec 2006 B2
7160590 Vanhamel et al. Jan 2007 B2
7165672 Fago et al. Jan 2007 B2
7191900 Opie et al. Mar 2007 B2
7198150 Blaschke et al. Apr 2007 B1
7234597 Rowe et al. Jun 2007 B2
7261205 Cervantes Aug 2007 B2
7328792 Benson Feb 2008 B1
7328794 Lubs et al. Feb 2008 B2
7334678 Kesler et al. Feb 2008 B2
7334679 Givens, Jr. Feb 2008 B2
7341147 Mallett et al. Mar 2008 B2
7353946 Cervantes Apr 2008 B2
7370759 Hommann May 2008 B2
7380658 Murray et al. Jun 2008 B2
7425207 Miller et al. Sep 2008 B2
7434686 Prindle Oct 2008 B2
7461741 State et al. Dec 2008 B2
7476223 Mcbride Jan 2009 B2
7490722 Mayda, II et al. Feb 2009 B2
7491176 Mann Feb 2009 B2
7495246 Fago et al. Feb 2009 B2
7549270 Rowe et al. Jun 2009 B2
7571804 Kjellmann et al. Aug 2009 B2
7597196 Langone Oct 2009 B2
7631777 Bukowski Dec 2009 B1
7640714 Waller et al. Jan 2010 B2
7678083 Stephens Mar 2010 B2
7692173 Fago et al. Apr 2010 B2
7694809 Garbini et al. Apr 2010 B2
7694810 Barry et al. Apr 2010 B1
7703625 Westphal Apr 2010 B2
7708719 Wilmot et al. May 2010 B2
7731048 Teixeira et al. Jun 2010 B2
7736341 Gollobin Jun 2010 B2
7743918 Itou et al. Jun 2010 B2
7755071 Polsinelli Jul 2010 B2
7766162 Maki et al. Aug 2010 B2
7766163 Tanghoej Aug 2010 B2
7770726 Murray et al. Aug 2010 B2
7798332 Brunet Sep 2010 B1
7815045 Delaney et al. Oct 2010 B2
7823722 Bezou et al. Nov 2010 B2
7837035 Duchamp et al. Nov 2010 B2
7850646 Segal Dec 2010 B2
7874426 Castellani Jan 2011 B2
7886906 Dunn Feb 2011 B1
7886907 Murray et al. Feb 2011 B2
7886908 Farrar et al. Feb 2011 B2
7900805 Shelton, IV et al. Mar 2011 B2
7905352 Wyrick Mar 2011 B2
7918009 Fago et al. Apr 2011 B2
7918010 Fago et al. Apr 2011 B2
7931167 Chmela Apr 2011 B2
7942286 Shiffer et al. May 2011 B2
7946441 Habitz et al. May 2011 B2
7954636 Vincent-aubry Jun 2011 B2
8011505 Murray et al. Sep 2011 B2
8025171 Cassol et al. Sep 2011 B2
8051981 Murray et al. Nov 2011 B2
8052673 Nestenborg Nov 2011 B2
8056716 Fonteyne et al. Nov 2011 B2
8056750 Vovan Nov 2011 B2
8066141 Casale et al. Nov 2011 B2
8079473 Matsuda et al. Dec 2011 B2
8096414 Finnestad et al. Jan 2012 B2
8109404 Chmela Feb 2012 B2
8113375 Jeon Feb 2012 B2
8127922 Nordholm et al. Mar 2012 B2
8127961 Vovan Mar 2012 B2
8162165 Reed Apr 2012 B2
8172082 Edwards et al. May 2012 B2
8172104 Weber May 2012 B2
8181778 Van Groningen et al. May 2012 B1
8201689 Kaern Jun 2012 B2
8205745 Murray et al. Jun 2012 B2
8226610 Edwards et al. Jul 2012 B2
8230993 Tangthoej Jul 2012 B2
8235209 Peck et al. Aug 2012 B2
8240468 Wilkinson et al. Aug 2012 B2
8267902 Martinsson Sep 2012 B2
8272526 Vovan et al. Sep 2012 B1
8303599 Hess et al. Nov 2012 B2
8322555 Chen Dec 2012 B2
8361026 Edwards et al. Jan 2013 B2
8371467 Jeon Feb 2013 B2
8397911 Bauman Mar 2013 B1
8434635 Wichelhaus May 2013 B2
8448804 Luburic May 2013 B2
8459455 Frojd Jun 2013 B2
8490790 Cocheteux et al. Jul 2013 B2
8499959 Chasid et al. Aug 2013 B2
8517996 Fontana Aug 2013 B2
8523843 Kavanagh et al. Sep 2013 B2
8534485 Van Jaarsveld Sep 2013 B2
8544645 Edwards et al. Oct 2013 B2
8556105 Ishii et al. Oct 2013 B2
8567602 Niederberger et al. Oct 2013 B2
8568373 Kuniyasu et al. Oct 2013 B2
8579115 Murphy et al. Nov 2013 B2
8584849 Mccaffrey Nov 2013 B2
8584850 Anderson et al. Nov 2013 B2
8608008 Gringras et al. Dec 2013 B2
8616215 Knajavi Dec 2013 B2
8672881 Nagamatsu Mar 2014 B2
8631935 Tomes et al. Apr 2014 B2
8684212 Stone et al. Apr 2014 B2
8684984 Bjerregaard et al. Apr 2014 B2
8695831 Schick Apr 2014 B2
8695832 Thielen et al. Apr 2014 B2
8701919 Messier Apr 2014 B2
8708999 Hong et al. Apr 2014 B2
8720685 Murray et al. May 2014 B2
8727117 Maasarani May 2014 B2
8733576 Jeon May 2014 B2
8734420 Ariagno et al. May 2014 B2
8740000 Moriyama et al. Jun 2014 B2
8746484 Thortensen-Woll et al. Jun 2014 B2
8752722 Kuhn et al. Jun 2014 B2
8794437 Cervantes Aug 2014 B2
8794470 Wambeke et al. Aug 2014 B2
8813955 Bottger et al. Aug 2014 B2
9333289 Hirschmann May 2016 B1
10342914 Hirschmann Jul 2019 B2
11357908 Hirschmann Jun 2022 B2
11541164 Hirschmann Jan 2023 B2
20040069667 Tommellini Apr 2004 A1
20060169611 Prindle Aug 2006 A1
20090145911 Hyde Jun 2009 A1
20090209031 Stopek Aug 2009 A1
20130081974 Hillard Apr 2013 A1
20130270137 Tumminello Oct 2013 A1
20140262884 Apothecary Sep 2014 A1
20140360903 Iio Dec 2014 A1
20140367383 Sellari et al. Dec 2014 A1
20150297296 Stauder Oct 2015 A1
20160038713 Kearns Feb 2016 A1
Foreign Referenced Citations (2)
Number Date Country
1042411 Sep 1966 GB
2016114867 Jul 2016 WO
Non-Patent Literature Citations (8)
Entry
WIPO International Search Report and Written Opinion of the ISA for related application (PCT/US15/64707), dated Sep. 22, 2016, 7 pages, submitted previously in connection with U.S. Appl. No. 16/506,753.
USPTO Office Action for related application (U.S. Appl. No. 16/506,753), dated Jul. 24, 2018, 10 pages, submitted previously in connection with U.S. Appl. No. 16/506,753.
AU Examination report for related application (2015-377191), dated Sep. 12, 2019, 3 pages, submitted previously in connection with U.S. Appl. No. 16/506,753.
Supplementary European Search Report (15878277.1-1122), dated Jan. 8, 2018, 8 pages, submitted previously in connection with U.S. Appl. No. 16/506,753.
USPTO Office Action for related application (U.S. Appl. No. 17/840,267), dated Aug. 11, 2021, 15 pages, submitted previously in connection with U.S. Appl. No. 17/840,267.
AU Examination report for related application (2020230336), dated May 10, 2021, 3 pages, submitted previously in connection with U.S. Appl. No. 17/840,267.
CA Examination report for related application (2967041), dated Feb. 1, 2022, 3 pages, submitted previously in connection with U.S. Appl. No. 17/840,267.
NZ Examination report for related application (731002), dated Jun. 3, 2022, 3 pages, submitted previously in connection with U.S. Appl. No. 17/840,267.
Related Publications (1)
Number Date Country
20230364324 A1 Nov 2023 US
Divisions (1)
Number Date Country
Parent 16506753 Jul 2019 US
Child 17840267 US
Continuations (3)
Number Date Country
Parent 17840267 Jun 2022 US
Child 18149513 US
Parent 15059428 Mar 2016 US
Child 16506753 US
Parent 14599202 Jan 2015 US
Child 15059428 US